ArticleNature2020
Small-molecule-induced polymerization triggers degradation of BCL6.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers.
0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed
11.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
135 citing papers in PubMed, 258 citations in OpenAlex.
- Dual E3 ligase recruitment by monovalent degraders for tunable SMARCA 2/4 degradation.Nature chemical biology · 2026Article
- Monovalent Nondegrading Molecular Glues: An Updated Overview of Emerging Mechanisms and Therapeutic Development.Pharmaceuticals (Basel, Switzerland) · 2026Review
- High-throughput ligand diversification to discover chemical inducers of proximity.Nature chemical biology · 2026Article
- Charged molecular glue discovery enabled by targeted degron display.Nature chemical biology · 2026Article
- A pharmacological modality to sequester homomeric proteins.Nature chemical biology · 2026Article
- A New Recruitable E3 Ligase UHRF1 Supporting Targeted Protein Degradation: A Minimal Azide as a Recruitment Ligand.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The emerging synergy of experimental and computational approaches for therapeutic modulation of biomolecular condensates.SLAS discovery : advancing life sciences R & D · 2026Review
- An SLCO2B1 mRNA Isoform Acts as a Noncoding RNA to Drive Cancer Progression by Triggering Protein Biosynthesis.Cancer research · 2026Article
- Molecular glue degraders: Rational design, specificity engineering, and advanced delivery.Acta pharmaceutica Sinica. B · 2026Review
- Ratiometric transcriptional activation by protein degradation.bioRxiv : the preprint server for biology · 2026Article
- Discovery and Structural Optimization of BRD4-Selective Monovalent Direct Degraders.ACS medicinal chemistry letters · 2026Article
- Small molecules modulate the biomolecular condensates and liquid‒liquid phase separation.Acta pharmaceutica Sinica. B · 2026Review
- Turning KEAP1 against NRF2.Nature chemical biology · 2026Article
- Age-related changes in Populus euphratica forests alter the structure and function of rhizosphere bacterial communities.World journal of microbiology & biotechnology · 2026Article
- Catalytic Proximal Protein Oligomerization as an Anti-Tumor Strategy Targeting WDR5.Nature communications · 2026Article
- Induced proximity-based therapeutic modalities.Nature reviews. Drug discovery · 2026Review
- Monovalent pseudo-natural products supercharge degradation of IDO1 by its native E3 KLHDC3.Nature chemistry · 2026Article
- Article
- Exploring Novel E3 Ligases and Neosubstrates for Molecular Glue Degraders and Therapeutic Applications in Cancer.Oncology research · 2026Review
- Novel Small Molecule DZ-865B Effectively Degrades BCL6, Promotes Apoptosis and Reduces Proliferation of Diffuse Large B-Cell Lymphoma Cells.Oncology research · 2026Article
75 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
21 authors at 4 institutions in 2 countries.
Mikołaj Słabicki *Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-6317-9296
Hojong Yoon *Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6062-5489
Jonas Koeppel *Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-1306-3994
Lena NitschBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Shourya S Roy BurmanDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9274-9104
Cristina Di GenuaBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Katherine A DonovanDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8539-5106
Adam S SperlingBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Moritz HunkelerDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0246-1188
Jonathan M TsaiBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Rohan SharmaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Andrew GuirguisBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-3134-0596
Charles ZouDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Priya ChudasamaPrecision Sarcoma Research Group, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Jessica A GasserBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Peter G MillerBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Claudia SchollDivision of Applied Functional Genomics, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.ORCID http://orcid.org/0000-0001-6768-322X
Stefan FröhlingDivision of Translational Medical Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.ORCID http://orcid.org/0000-0001-7907-4595
Radosław P NowakDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0605-0071
Eric S FischerDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. eric_fischer@dfci.harvard.edu.ORCID http://orcid.org/0000-0001-7337-6306
Benjamin L EbertBroad Institute of MIT and Harvard, Cambridge, MA, USA. benjamin_ebert@dfci.harvard.edu.ORCID http://orcid.org/0000-0003-0197-5451
Broad Institute · USHarvard University · USGerman Cancer Research Center · DEDana-Farber Cancer Institute · US
Funding
TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI SCOTT A ARMSTRONG · 1996 to 2026
$52.5MTargeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI ASTER, JON C. · 2017 to 2021
$10.6MTyrosine Kinases, Serine-Threonine Kinases,&Phosophatases in PathogenesisP01CA108631 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ESTEY, ELIHU · 2005 to 2009
$9.7MFunctional Genomic Dissection of Refractory AnemiaR01HL082945 · NHLBI · DANA-FARBER CANCER INSTITUTE · PI EBERT, BENJAMIN LEVINE · 2005 to 2022
$6.8MThe role of clonal hematopoiesis in the development and therapy of myeloid malignanciesR35CA253125 · NCI · DANA-FARBER CANCER INST · PI EBERT, BENJAMIN LEVINE · 2020 to 2024
$4.9MDegrading therapeutically important kinases using small moleculesR01CA218278 · NCI · STANFORD UNIVERSITY · PI Eric Sebastian Fischer, NATHANAEL Schiander GRAY · 2019 to 2026
$4.6MThe molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase.R01CA214608 · NCI · DANA-FARBER CANCER INST · PI Eric Sebastian Fischer · 2017 to 2026
$4.0MExpanding pharmacological modalities for targeted cancer therapyF99CA253754 · NCI · HARVARD UNIVERSITY · PI YOON, HOJONG · 2020 to 2020
$33kHoward Hughes Medical InstituteNCI NIH HHS F99 CA253754NCI NIH HHS P01 CA066996NCI NIH HHS P01 CA108631NCI NIH HHS P50 CA206963NCI NIH HHS R01 CA214608NCI NIH HHS R01 CA218278NCI NIH HHS R35 CA253125NHLBI NIH HHS R01 HL082945
Abstract
Effective and sustained inhibition of non-enzymatic oncogenic driver proteins is a major pharmacological challenge. The clinical success of thalidomide analogues demonstrates the therapeutic efficacy of drug-induced degradation of transcription factors and other cancer targets
Indexed as
Cryoelectron MicroscopyHumansIn Vitro TechniquesLigandsModels, MolecularNuclear ProteinsPolymerizationProteasome Endopeptidase ComplexProteolysisProto-Oncogene Proteins c-bcl-6Seven in Absentia ProteinsSolventsSynthetic BiologyUbiquitinationUbiquitin-Protein LigasesBCL6 protein, humanLigandsNuclear ProteinsProteasome Endopeptidase ComplexProto-Oncogene Proteins c-bcl-6Seven in Absentia ProteinsSolventsUbiquitin-Protein Ligases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.